89bio Inc (ETNB)

Currency in USD
14.84
0.00(0.00%)
Closed·
Showing 89bio historical data. For real-time data please try another search
Fair Value
Day's Range
14.8214.87
52 wk Range
4.1615.06
Key Statistics
Prev. Close
14.84
Open
14.83
Day's Range
14.82-14.87
52 wk Range
4.16-15.06
Volume
55.65M
Average Volume (3m)
5.46M
1-Year Change
62.3632%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ETNB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

89bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

89bio Inc Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as 89Bio Ltd. and changed its name to September 2019. The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.

89bio Inc SWOT Analysis


Pegozafermin's Promise
Explore 89bio's lead candidate in Phase III trials for MASH and SHTG, potentially unlocking billion-dollar market opportunities in liver and cardio-metabolic diseases
Market Dynamics
Delve into the evolving landscape of MASH treatments, including the impact of GLP-1 therapies and how pegozafermin aims to differentiate itself
Financial Outlook
Analyst targets range from $12 to $49 per share, reflecting varied assumptions about pegozafermin's potential across multiple indications
Strategic Positioning
Learn how 89bio's pipeline-in-a-product strategy and favorable regulatory environment could shape its future in the competitive biopharmaceutical space
Read full SWOT analysis

Compare ETNB to Peers and Sector

Metrics to compare
ETNB
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x−0.6x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x2.6x
Price / LTM Sales
0.0x0.0x3.3x
Upside (Analyst Target)
0.0%0.0%44.9%
Fair Value Upside
Unlock0.0%5.6%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-- / -0.5069
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ETNB Income Statement

People Also Watch

766.92
ARGX
-0.60%
20.96
APLS
-3.14%
31.49
TDC
+1.68%
34.410
ORKA
+0.26%
3.280
MNKD
+1.23%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.